Lantheus Holdings (LNTH) Company Report

The Portnoy Law Firm announced a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH) on behalf of investors who bought securities between February 26, 2025, and August 5, 2025.
Investors have until November 10, 2025, to file a lead plaintiff motion in this lawsuit.
The complaint alleges that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, its key prostate cancer imaging product, by concealing that price hikes and competitive pressures were eroding its market position.
This alleged misrepresentation led to investors purchasing shares at artificially inflated prices, with the stock dropping over 23% and 28% following May and August 2025 quarterly results that revealed sharp sales declines, reduced guidance, and intensifying competition.

Nov 10, 2025, 5:20 PM

Press Release

Lantheus Holdings Faces Securities Class Action Lawsuit

LNTH

Legal Proceedings

Demand Weakening

Profit Warning

Faruqi & Faruqi, LLP is investigating potential claims against Lantheus Holdings, Inc. (LNTH) regarding alleged misleading statements concerning the competitive position, pricing, revenue, and growth potential of its product, Pylarify.
Investors who purchased Lantheus securities between November 6, 2024, and August 6, 2025, are encouraged to contact the firm.
The deadline for investors to seek the role of lead plaintiff in the federal securities class action is November 10, 2025.
The lawsuit stems from disappointing first quarter results reported on May 7, 2025, and further reduced growth expectations for Pylarify announced on August 6, 2025, which led to a 28.8% decline in Lantheus's stock price on August 6, 2025.

Nov 9, 2025, 1:50 PM

Press Release

Lantheus Reports Q3 2025 Results, Updates Full-Year Guidance, and Announces Leadership Transition

LNTH

Earnings

Guidance Update

Management Change

Q3 2025 consolidated net revenue was $384 million, an increase of 1.4% year-over-year, with adjusted EPS of $1.27, a decrease of 25.3%.
The company narrowed its full-year 2025 revenue guidance to $1.49-$1.51 billion and adjusted EPS guidance to $5.50-$5.65.
CEO Brian Markison will retire at the end of 2025, with Board Chairperson Mary Anne Heino assuming the role of interim CEO; President Paul Blanchfield is also leaving the company.
Polarify sales were $240.6 million, down 7.4% year-over-year, though U.S. volumes increased 3.3% and pricing stabilization was observed.
Lantheus is advancing its pipeline, including preparing for potential approval of a new F18 PSMA PET formulation in 2026 and MK-6240 (tau imaging agent) with a PDUFA date of August 13, 2026.

Nov 6, 2025, 1:00 PM

Transcript

Lantheus Reports Q3 2025 Results, Updates Guidance, and Announces Leadership Transition

LNTH

Earnings

Guidance Update

Management Change

Lantheus reported Q3 2025 consolidated net revenue of $384 million, an increase of 1.4%, and adjusted diluted EPS of $1.27, a decrease of 25.3%. Polarify sales were $240.6 million, down 7.4%, while Definity sales grew 6.3% to $81.8 million.
The company updated its full-year 2025 guidance, narrowing revenue to $1.49-$1.51 billion and adjusted EPS to $5.50-$5.65. Polarify and NeuroSeq are expected to trend towards the higher end of their respective prior ranges.
CEO Brian Markison announced his retirement at the end of 2025, with Board Chairperson Mary Anne Heino assuming the role of Executive Chairperson and interim CEO; President Paul Blanchfield will also be leaving. A comprehensive CEO search has been initiated.
Lantheus is preparing for the potential approval of its new F18 PSMA PET formulation in 2026, which is anticipated to qualify for three years of transitional pass-through payment status. The FDA has set a PDUFA date of August 13, 2026, for MK-6240, an F18 PET imaging agent for tau in Alzheimer's disease.
During Q3, the company invested $100 million in share repurchases and completed the acquisition of Life Molecular Imaging for approximately $309 million net of cash acquired.

Nov 6, 2025, 1:00 PM

Transcript

Lantheus Announces Q3 2025 Results and Updates FY 2025 Guidance

LNTH

Earnings

Guidance Update

M&A

Lantheus reported Q3 2025 revenues of $384.0 million, a 1.4% increase year-over-year, and adjusted EPS of $1.27, a 25.3% decrease from Q3 2024.
Key product sales for Q3 2025 included PYLARIFY at $240.6 million and DEFINITY at $81.8 million, which grew 6.3% year-over-year, with Neuraceq contributing $20.442 million after its addition during the quarter.
The company updated its FY 2025 guidance, narrowing its revenue outlook to $1.49 billion to $1.51 billion and adjusting its adjusted fully diluted EPS to $5.50 to $5.65.
Lantheus completed the acquisition of Life Molecular Imaging and repurchased $100 million of stock during Q3 2025, supported by $382.0 million in cash on hand and $750.0 million in available revolving credit.
The company anticipates four key product approvals by year-end 2026, including new PSMA PET, MK-6240, and LNTH-2501 with PDUFA dates in March and August 2026.

Nov 6, 2025, 1:00 PM

Presentation

Lantheus Announces Q3 2025 Results, Leadership Transition, and Updated Full-Year Guidance

LNTH

Earnings

Management Change

Guidance Update

Lantheus announced a leadership transition, with CEO Brian Markison retiring at the end of 2025 and Mary Anne Heino assuming the role of Executive Chairperson and interim CEO, while President Paul Blanchfield will also be leaving the company.
For Q3 2025, consolidated net revenue was $384 million, an increase of 1.4%, with PYLARIFY sales at $240.6 million, down 7.4% year-over-year, and adjusted diluted earnings per share (EPS) of $1.27, a decrease of 25.3%.
The company narrowed its full-year 2025 revenue guidance to $1.49 billion-$1.51 billion and adjusted EPS guidance to $5.50-$5.65, with PYLARIFY and Neuraceq expected to trend towards the higher end of their respective ranges.
Lantheus is preparing for the potential approval of a new F18 PSMA PET formulation in 2026 and announced an FDA PDUFA date of August 13, 2026, for MK-6240, its F18 PET imaging agent for detecting tau in Alzheimer's disease.

Nov 6, 2025, 1:00 PM

Transcript

Lantheus Reports Q3 2025 Results, Announces CEO Retirement, and Updates Guidance

LNTH

Earnings

CEO Change

Guidance Update

Lantheus reported worldwide revenue of $384.0 million, adjusted fully diluted earnings per share of $1.27, and free cash flow of $94.7 million for the third quarter ended September 30, 2025.
CEO Brian Markison will retire effective December 31, 2025, with former CEO Mary Anne Heino appointed Executive Chairperson effective November 7, 2025, and Interim CEO effective January 1, 2026. Additionally, President Paul Blanchfield is leaving the company.
The company updated its full-year 2025 revenue guidance to $1.49 billion - $1.51 billion and adjusted fully diluted EPS guidance to $5.50 - $5.65.
Lantheus repurchased $100 million of common stock in the third quarter of 2025 and completed the acquisition of Life Molecular Imaging in July.

Nov 6, 2025, 12:39 PM

8-K

Lantheus Holdings Faces Class Action Lawsuit

LNTH

Legal Proceedings

Profit Warning

Demand Weakening

The Portnoy Law Firm announced a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH) on behalf of investors who purchased securities between February 26, 2025 and August 5, 2025.
Investors have until November 10, 2025 to file a lead plaintiff motion.
The complaint alleges that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, its key prostate cancer imaging product, by concealing that price hikes and competitive pressures were eroding its market position.
This alleged misrepresentation led to investors purchasing shares at artificially inflated prices, as quarterly results in May and August 2025 revealed sharp sales declines, reduced guidance, and intensifying competition, causing the stock to drop over 23% and 28% on those respective dates.

Nov 5, 2025, 4:14 PM

Press Release

Faruqi & Faruqi Investigates Lantheus Holdings Over Securities Claims

LNTH

Legal Proceedings

Demand Weakening

Profit Warning

Faruqi & Faruqi, LLP is investigating potential securities claims against Lantheus Holdings, Inc. (LNTH) regarding alleged misleading statements concerning Pylarify's competitive position, pricing, revenue, and growth potential.
Investors who suffered losses exceeding $10,000 between February 26, 2025, and August 5, 2025, are encouraged to contact the firm.
The investigation follows a 28.8% decline in Lantheus's common stock price on August 6, 2025, from $72.83 to $51.87 per share, after the company announced disappointing Q1 results and significantly reduced growth expectations for Pylarify.
The deadline to seek the role of lead plaintiff in the federal securities class action is November 10, 2025.

Nov 4, 2025, 4:59 PM

Press Release

Lantheus Holdings Faces Class Action Lawsuit

LNTH

Legal Proceedings

Demand Weakening

Profit Warning

The Portnoy Law Firm has announced a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH) on behalf of investors who bought securities between February 26, 2025, and August 5, 2025.
The complaint alleges that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, its key prostate cancer imaging product, by concealing that price hikes and competitive pressures were eroding its market position.
Quarterly results in May and August 2025 revealed sharp sales declines, reduced guidance, and intensifying competition, leading to Lantheus's stock dropping over 23% and 28% on those respective dates.
Investors have until November 10, 2025, to file a lead plaintiff motion.

Nov 4, 2025, 2:00 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for LNTH.

No recent filings or transcripts found for LNTH.